Tour the DUPIXENT virtual booth experience. Explore Today DUP.21.05.0061

DELIVER
PROVEN RESULTS.
CELEBRATE
LASTING RELIEF.

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.1

When topical Rx therapies ARE NOT ENOUGH,
DUPIXENT is your first-line systemic treatment
View the sustained results in adults

In uncontrolled moderate-to-severe atopic dermatitis

DUPIXENT demonstrated rapid and sustained results in
adults and avoids broad immunosuppression1

It is unknown if DUPIXENT will influence the immune response against helminth infections.

SEE CLINICAL RESULTS overview

Specifically targets IL-4 and IL-13 signaling

DUPIXENT is the first and only therapy to specifically target the IL-4Rα, thereby inhibiting IL-4 and IL-13 signaling and helping to reduce type 2 inflammation1,2

Explore the Mechanism
of Action (MOA)

Safety data

View safety data across clinical trials

SEE SAFETY DATA

One dose every 2 or 4 weeks (based on age and weight) after initial loading dose1

Explore appropriate dosing schedules and weight-tiered regimens for DUPIXENT, which does not require initial lab testing or ongoing lab monitoring according to the Prescribing Information.

DUPIXENT is available in a 200 mg or 300 mg pre-filled pen (for patients 12+ years of age) or pre-filled syringe for subcutaneous injection.

See Dosing and Administration
NOW AVAILABLE
200 mg PRE-FILLED PEN

DUPIXENT is available in a 200 mg or 300 mg pre-filled pen (for patients
aged 12+ years) or pre-filled syringe for subcutaneous injection.1

SEE ADMINISTRATION OPTIONS

Samples may be available—speak with your DUPIXENT representative for more information, or click here to contact a representative.

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one‑on‑one nursing support, and more.

Learn how we can help

DUPIXENT MyWay Enrollment Forms:

English
Spanish

Check formulary status in your area

See the coverage status for DUPIXENT, prior authorization, and step edit information by zip code.

Look up coverage
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.
Contact a Rep

References:

  1. DUPIXENT Prescribing Information.
  2. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indication

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.